SK Plasma announced on the 13th that it has signed an exclusive domestic sales contract with Janssen Korea for the treatment of myeloid dysplasia syndrome and acute myeloid leukemia.

Under the agreement, SK Plasma will be in charge of the domestic distribution and marketing of Dakogen, while Janssen Korea will be in charge of producing and supplying products. Dacogen is an intravenous anticancer drug essential for myeloid dysplasia syndrome and acute myeloid leukemia.
Myeloid dysplasia syndrome is one of the blood cancers that occur in the bone marrow and is a disease characterized by abnormal blood cell formation in the bone marrow and reduction of normal white blood cells, red blood cells, and